(CercleFinance.com) – Bruno Lafont, the co-founder and deputy CEO of NFL Biosciences, announced on Wednesday that he had increased his stake in the biopharmaceutical company.
The entrepreneur, who co-founded the company in 2006, now says he owns 8.86% of the capital, against 4.18% before the operation.
In detail, the businessman exercised in full 50,000 business creator share subscription warrants (BSPCE) which enabled him to subscribe to 500,000 new shares at a price of 0.10 euro, generating a contribution of 50,000 euros for NFL.
Bruno Lafont, who is in charge of structuring and development at NFL Biosciences, says he chose to strengthen his capital because of his confidence in the capacity of the clinical study conducted in smoking cessation.
He believes that this should provide a first demonstration of effectiveness to regulatory authorities, which would allow NFL to ‘change dimension’.
Within the management team of NFL Biosciences, Bruno Lafont manages in particular the implementation of clinical studies and the scientific activities of the company.
Following the exercise of its BSPCEs, the company’s capital was increased to 8.1 million shares, compared to 7.6 million before exercise, with potential capital now amounting to 9.2 million. i.e. a potential dilution of 13%, against 39% previously.
For personal financial reasons, Bruno Lafont plans to sell a maximum of 100,000 titles over the next 12 months.
2023-07-06 09:11:00
#NFL #Biosciences #founders #strengthens #capital
/origin-imgresizer.eurosport.com/2023/07/25/3751062-76311168-2560-1440.jpg?fit=300%2C300&ssl=1)
